T. Rowe Price Associates
PLRX icon

T. Rowe Price Associates’s Pliant Therapeutics PLRX Stock Holding History

T. Rowe Price Associates’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-83,868
Closed -$98K – 3101
2025
Q2 		$98K Sell
83,868
-3,806
-4% -$5.38K ﹤0.01% 2899
2025
Q1 		$119K Sell
87,674
-4,546,812
-98% -$27.6M ﹤0.01% 2783
2024
Q4 		$61M Sell
4,634,486
-200,327
-4% -$2.74M 0.01% 694
2024
Q3 		$54.2M Buy
4,834,813
+232,490
+5% +$2.91M 0.01% 737
2024
Q2 		$49.5M Buy
4,602,323
+643,235
+16% +$8.29M 0.01% 729
2024
Q1 		$59M Buy
3,959,088
+173,172
+5% +$2.86M 0.01% 684
2023
Q4 		$68.6M Buy
3,785,916
+434,429
+13% +$6.61M 0.01% 617
2023
Q3 		$58.1M Buy
3,351,487
+380,554
+13% +$6.6M 0.01% 641
2023
Q2 		$53.8M Buy
2,970,933
+864,689
+41% +$20.5M 0.01% 684
2023
Q1 		$56M Buy
2,106,244
+900,510
+75% +$25.6M 0.01% 655
2022
Q4 		$23.3M Sell
1,205,734
-26,110
-2% -$546K ﹤0.01% 869
2022
Q3 		$25.7M Buy
+1,231,844
New +$23.6M ﹤0.01% 833
2021
Q3 		– Sell
-210,678
Closed -$6.13M – 2977
2021
Q2 		$6.13M Sell
210,678
-3,479
-2% -$108K ﹤0.01% 1474
2021
Q1 		$8.42M Buy
+214,157
New +$6.95M ﹤0.01% 1418

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

T. Rowe Price Associates's PLRX Position: Q3 2025 in Review

T. Rowe Price Associates sold out of Pliant Therapeutics (PLRX) in Q3 2025, closing a stake of 83,868 shares — an estimated $98K sold.

T. Rowe Price Associates first reported a position in PLRX in Q1 2021 and held it in 14 quarters. The position peaked at $68.6M in Q4 2023. 99 funds tracked by Wall St. Rank hold PLRX as of Q3 2025.

  • T. Rowe Price Associates reported no remaining Pliant Therapeutics position as of Q3 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 83,868 Pliant Therapeutics shares in Q3 2025, an estimated $98K.
  • T. Rowe Price Associates first reported a position in Pliant Therapeutics in Q1 2021 and held it in 14 quarters.
  • T. Rowe Price Associates's Pliant Therapeutics position peaked at $68.6M in Q4 2023.
  • 99 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2025.

Based on T. Rowe Price Associates's 13F filing for Q3 2025, filed 14 Nov 2025.